Table 1 Trial characteristics

Registered

44 (59%)

Funding

 Industry

54 (73%)

  Government

4 (5%)

  Institution

2 (3%)

  Not-for-profit

0 (0%)

  None

1 (1%)

  Not reported

13 (17%)

 Mean age

41

 Male (%)

16%

 Migraine with aura (%)

18 (45%)

 Prior prophylaxis (%)

28 (49%)

 Mean migraine days/month

11

 Interventions

 Amitriptyline

7 (10%)

  Beta-blockers

13 (18%)

  Calcium Channel Blockers

8 (11%)

  Carismabate

2 (3%)

  Eptinezumab

5 (7%)

  Erenumab

9 (13%)

  Fremanezumab

7 (10%)

  Gabapentin

2 (3%)

  Galcanezumab

7 (10%)

  Gepants

4 (6%)

  Oxcarbazepine

1 (1%)

  Pregabalin

1 (1%)

  Topiramate

13 (18%)

  Valproate

8 (11%)